Gyre Therapeutics Acquires Cullgen in $300 Million All-Stock Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Should l Buy PULM?
Source: stocktwits
- Acquisition Details: Gyre Therapeutics announced its acquisition of Cullgen in an all-stock transaction valued at approximately $300 million, with Cullgen set to become a wholly owned subsidiary, and the deal expected to close in early Q2 2026 pending U.S. regulatory approvals.
- Market Reaction: Following the announcement, GYRE's shares rose by 8%, indicating a positive market response to the acquisition, although the stock has lost 22% over the past 12 months, reflecting cautious optimism among investors regarding future growth prospects.
- Challenges for Pulmatrix: Pulmatrix's stock plummeted 36% after the termination of its merger agreement with Cullgen, and the company is now actively seeking alternative merger opportunities, highlighting the uncertainty and pressure faced in the industry consolidation landscape.
- Regulatory Hurdles: Pulmatrix noted that it did not receive the necessary approval from the China Securities Regulatory Commission, which led to the termination of the deal with Cullgen, underscoring the complexities and potential risks associated with cross-border transactions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PULM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PULM
About PULM
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gyre Therapeutics Acquires Cullgen in $300 Million All-Stock Deal
- Acquisition Details: Gyre Therapeutics announced its acquisition of Cullgen in an all-stock transaction valued at approximately $300 million, with Cullgen set to become a wholly owned subsidiary, and the deal expected to close in early Q2 2026 pending U.S. regulatory approvals.
- Market Reaction: Following the announcement, GYRE's shares rose by 8%, indicating a positive market response to the acquisition, although the stock has lost 22% over the past 12 months, reflecting cautious optimism among investors regarding future growth prospects.
- Challenges for Pulmatrix: Pulmatrix's stock plummeted 36% after the termination of its merger agreement with Cullgen, and the company is now actively seeking alternative merger opportunities, highlighting the uncertainty and pressure faced in the industry consolidation landscape.
- Regulatory Hurdles: Pulmatrix noted that it did not receive the necessary approval from the China Securities Regulatory Commission, which led to the termination of the deal with Cullgen, underscoring the complexities and potential risks associated with cross-border transactions.
See More
Cullgen Terminates Merger Agreement with Pulmatrix
- Merger Agreement Termination: On February 28, 2026, Cullgen notified Pulmatrix of the termination of their merger agreement, a decision driven by significant delays in approval from the China Securities Regulatory Commission, which adversely affects Pulmatrix's strategic growth plans.
- Pursuing Alternative Opportunities: Pulmatrix is actively seeking other merger opportunities; despite the uncertainty following Cullgen's exit, the company's executives express optimism about increased transaction activity within the industry, indicating potential market vitality.
- Historical Context: The merger agreement between Pulmatrix and Cullgen was initially signed in November 2024 and received shareholder approval in 2025, but the failure to secure necessary regulatory approvals from China ultimately prevented the deal from closing, highlighting the complexities of cross-border mergers.
- Technology and Product Line: Pulmatrix focuses on developing innovative inhaled therapeutic products for migraine and respiratory diseases using its proprietary iSPERSE™ technology aimed at enhancing drug delivery efficacy; despite the merger's failure, the company will continue to advance its product pipeline.
See More
Pulmatrix Reports Q4 Results with Significant Losses
- Financial Performance: Pulmatrix reported a GAAP EPS of -$1.41 for Q4, indicating significant challenges in profitability and reflecting ongoing financial pressure on the company.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents stood at $4.1 million, a substantial decrease from $9.5 million at the end of 2024, highlighting difficulties in cash management.
- Operational Funding Outlook: The company anticipates that its current cash position, based on operational efficiencies and spending prioritization, is sufficient to fund operations into Q1 2027, providing a degree of safety but still raising concerns about future liquidity.
- Market Reaction: Pulmatrix's financial results and cash flow situation may negatively impact investor confidence, particularly given the ongoing losses, which could affect its stock performance and market valuation.
See More
Pulmatrix Reports 2025 Financial Results and Merger Progress
- Deteriorating Financial Condition: Pulmatrix reported zero revenue for 2025, down from $7.8 million in 2024, indicating a significant decline in market competitiveness that could adversely affect future fundraising capabilities and investor confidence.
- Significant Reduction in R&D Spending: Research and development expenses plummeted from $7.2 million in 2024 to less than $0.1 million, primarily due to the wind-down of the PUR1900 clinical trial, which may hinder the company's ability to develop new products and impact long-term growth potential.
- Slow Merger Progress: The merger with Cullgen is still pending approval from the China Securities Regulatory Commission, with both parties agreeing to waive the
See More
Pulmatrix and Cullgen Update on Merger Approval Process
- Merger Agreement Progress: Pulmatrix and Cullgen have mutually agreed to waive the 'No Solicitation' clause in their merger agreement, allowing both parties to explore alternative transactions while still seeking approval from the China Securities Regulatory Commission, which could open new strategic collaboration opportunities.
- Regulatory Approval Delay: Despite Pulmatrix's merger agreement receiving shareholder approval in June 2025, the lack of approval from the China Securities Regulatory Commission may impact the final completion timeline of the merger and the company's future funding operations.
- Cash Flow Status: As of September 30, 2025, Pulmatrix reported a cash and cash equivalents balance of $4.8 million, which is anticipated to be sufficient to fund operations into the fourth quarter of 2026 based on current operational efficiencies and spending priorities, providing a financial buffer during the merger process.
- Clinical Assets and Technology: Pulmatrix focuses on developing inhaled therapeutic products for migraine and respiratory diseases using its proprietary iSPERSE™ technology, which aims to optimize drug delivery and improve patient outcomes, showcasing the company's innovative potential in the biopharmaceutical sector.
See More
Pulmatrix and Cullgen Update on Merger Approval Process
- Merger Agreement Progress: Pulmatrix and Cullgen have mutually agreed to waive the 'No Solicitation' clause in their merger agreement, allowing both parties to explore alternative transactions while still seeking approval from the CSRC, which may open new opportunities for both companies.
- Regulatory Approval Delay: Despite Pulmatrix's merger agreement receiving shareholder approval in June 2025, the lack of approval from the CSRC may affect the final completion timeline of the merger, increasing uncertainty for stakeholders.
- Financial Position: As of September 30, 2025, Pulmatrix reported cash and cash equivalents of $4.8 million, which is anticipated to fund operations into the fourth quarter of 2026, indicating prudent financial management amidst ongoing merger discussions.
- Clinical Asset Development: Pulmatrix's iSPERSE™ technology shows promise across multiple clinical assets, particularly with PUR3100 receiving FDA IND approval and PUR1800 demonstrating favorable results in a Phase 1b study for AECOPD, suggesting potential market opportunities ahead.
See More
Gyre Therapeutics Acquires Cullgen in $300 Million All-Stock Deal
- Acquisition Details: Gyre Therapeutics announced its acquisition of Cullgen in an all-stock transaction valued at approximately $300 million, with Cullgen set to become a wholly owned subsidiary, and the deal expected to close in early Q2 2026 pending U.S. regulatory approvals.
- Market Reaction: Following the announcement, GYRE's shares rose by 8%, indicating a positive market response to the acquisition, although the stock has lost 22% over the past 12 months, reflecting cautious optimism among investors regarding future growth prospects.
- Challenges for Pulmatrix: Pulmatrix's stock plummeted 36% after the termination of its merger agreement with Cullgen, and the company is now actively seeking alternative merger opportunities, highlighting the uncertainty and pressure faced in the industry consolidation landscape.
- Regulatory Hurdles: Pulmatrix noted that it did not receive the necessary approval from the China Securities Regulatory Commission, which led to the termination of the deal with Cullgen, underscoring the complexities and potential risks associated with cross-border transactions.
See More
Cullgen Terminates Merger Agreement with Pulmatrix
- Merger Agreement Termination: On February 28, 2026, Cullgen notified Pulmatrix of the termination of their merger agreement, a decision driven by significant delays in approval from the China Securities Regulatory Commission, which adversely affects Pulmatrix's strategic growth plans.
- Pursuing Alternative Opportunities: Pulmatrix is actively seeking other merger opportunities; despite the uncertainty following Cullgen's exit, the company's executives express optimism about increased transaction activity within the industry, indicating potential market vitality.
- Historical Context: The merger agreement between Pulmatrix and Cullgen was initially signed in November 2024 and received shareholder approval in 2025, but the failure to secure necessary regulatory approvals from China ultimately prevented the deal from closing, highlighting the complexities of cross-border mergers.
- Technology and Product Line: Pulmatrix focuses on developing innovative inhaled therapeutic products for migraine and respiratory diseases using its proprietary iSPERSE™ technology aimed at enhancing drug delivery efficacy; despite the merger's failure, the company will continue to advance its product pipeline.
See More
Pulmatrix Reports Q4 Results with Significant Losses
- Financial Performance: Pulmatrix reported a GAAP EPS of -$1.41 for Q4, indicating significant challenges in profitability and reflecting ongoing financial pressure on the company.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents stood at $4.1 million, a substantial decrease from $9.5 million at the end of 2024, highlighting difficulties in cash management.
- Operational Funding Outlook: The company anticipates that its current cash position, based on operational efficiencies and spending prioritization, is sufficient to fund operations into Q1 2027, providing a degree of safety but still raising concerns about future liquidity.
- Market Reaction: Pulmatrix's financial results and cash flow situation may negatively impact investor confidence, particularly given the ongoing losses, which could affect its stock performance and market valuation.
See More
Pulmatrix Reports 2025 Financial Results and Merger Progress
- Deteriorating Financial Condition: Pulmatrix reported zero revenue for 2025, down from $7.8 million in 2024, indicating a significant decline in market competitiveness that could adversely affect future fundraising capabilities and investor confidence.
- Significant Reduction in R&D Spending: Research and development expenses plummeted from $7.2 million in 2024 to less than $0.1 million, primarily due to the wind-down of the PUR1900 clinical trial, which may hinder the company's ability to develop new products and impact long-term growth potential.
- Slow Merger Progress: The merger with Cullgen is still pending approval from the China Securities Regulatory Commission, with both parties agreeing to waive the
See More
Pulmatrix and Cullgen Update on Merger Approval Process
- Merger Agreement Progress: Pulmatrix and Cullgen have mutually agreed to waive the 'No Solicitation' clause in their merger agreement, allowing both parties to explore alternative transactions while still seeking approval from the China Securities Regulatory Commission, which could open new strategic collaboration opportunities.
- Regulatory Approval Delay: Despite Pulmatrix's merger agreement receiving shareholder approval in June 2025, the lack of approval from the China Securities Regulatory Commission may impact the final completion timeline of the merger and the company's future funding operations.
- Cash Flow Status: As of September 30, 2025, Pulmatrix reported a cash and cash equivalents balance of $4.8 million, which is anticipated to be sufficient to fund operations into the fourth quarter of 2026 based on current operational efficiencies and spending priorities, providing a financial buffer during the merger process.
- Clinical Assets and Technology: Pulmatrix focuses on developing inhaled therapeutic products for migraine and respiratory diseases using its proprietary iSPERSE™ technology, which aims to optimize drug delivery and improve patient outcomes, showcasing the company's innovative potential in the biopharmaceutical sector.
See More
Pulmatrix and Cullgen Update on Merger Approval Process
- Merger Agreement Progress: Pulmatrix and Cullgen have mutually agreed to waive the 'No Solicitation' clause in their merger agreement, allowing both parties to explore alternative transactions while still seeking approval from the CSRC, which may open new opportunities for both companies.
- Regulatory Approval Delay: Despite Pulmatrix's merger agreement receiving shareholder approval in June 2025, the lack of approval from the CSRC may affect the final completion timeline of the merger, increasing uncertainty for stakeholders.
- Financial Position: As of September 30, 2025, Pulmatrix reported cash and cash equivalents of $4.8 million, which is anticipated to fund operations into the fourth quarter of 2026, indicating prudent financial management amidst ongoing merger discussions.
- Clinical Asset Development: Pulmatrix's iSPERSE™ technology shows promise across multiple clinical assets, particularly with PUR3100 receiving FDA IND approval and PUR1800 demonstrating favorable results in a Phase 1b study for AECOPD, suggesting potential market opportunities ahead.
See More
